EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer

Avi S Baskin iD, Karen E Hoffman, David F Penson iD, Li-Ching Huang iD, Zhiguo Zhao iD, Bashir Al Hussein Al Awamlh iD, Daniel D Joyce iD, Alicia K Morgans, Jeffrey J Tosoian, Christopher J D Wallis iD, Michael Goodman iD, Ann S Hamilton iD und 6 weitere

BJU International · 2026-12 · 138 (6) · 1053-1064

DOI: 10.1111/bju.70410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 12.08.2026. Verfasst von Avi S Baskin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of California Irvine, Irvine, CA, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Patient-Centered Outcomes Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To report long‐term oncological outcomes for men with clinically localised prostate cancer (PCa) treated with contemporary modalities in a population‐based United States cohort. Patients and Methods The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study prospectively enrolled men with clinically localised PCa from 2011 to 2012. Patients were stratified into two groups: favourable prognosis (clinical T stage [cT]1–T2a/bN0M0, prostate‐specific antigen [PSA] level ≤ 20 ng/mL, Grade Group 1–2) and unfavourable prognosis (cT2cN0M0, PSA level 20–50 ng/mL, or Grade Group 3–5). Main outcomes were PCa‐specific mortality (PCSM), composite progression to advanced disease (metastasis, PCSM event, or systemic therapy), and overall survival (OS). Cox regression models adjusted for demographic and clinical covariates.

Results

Of the 2604 men included, 73% were White, 15% Black, and 7% Hispanic. All hazard ratios (HRs) were adjusted for demographic and clinical covariates using multivariable Cox and Fine‐Gray models. In the favourable group, compared with surgery, external beam radiotherapy (EBRT; HR 1.5, 95% confidence interval [CI] 1.1–2.1, P < 0.01), brachytherapy (HR 2.1, 95% CI 1.3–3.3, P < 0.01), and active surveillance (HR 1.5, 95% CI 1.1–2.1, P = 0.02) were associated with higher all‐cause mortality; the 10‐year cumulative incidence of PCSM was ≤1.5% for all five strategies, and progression did not differ. In the unfavourable group, EBRT was associated with worse OS (HR 2.8, 95% CI 1.9–4.3, P < 0.01), with no adjusted differences in PCSM (10‐year cumulative incidence 3.5% after surgery vs 8.8% after EBRT) or progression across treatments.

Conclusion

In this population‐based cohort treated with contemporary modalities, the 10‐year risk of PCa death was low across all treatment strategies, including active surveillance. OS differences favouring surgery likely reflect residual confounding from baseline health and treatment selection. These findings underscore the importance of patient values and comorbidities in shared decision‐making for localised PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleProspective StudiesAgedMiddle AgedTreatment OutcomeProstatectomyPrognosisDisease ProgressionUnited StatesProstate-Specific Antigen

Stichwörter der Autor:innen

cohort studiespatient‐reported outcome measuresprospective studiesprostatic neoplasmssurvey and questionnaires

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University of California Irvine, Irvine, CA, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Center, Nashville, TN, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, USA.

ORCID-Profile: Avi S Baskin, David F Penson, Li-Ching Huang, Zhiguo Zhao, Bashir Al Hussein Al Awamlh, Daniel D Joyce, Christopher J D Wallis, Michael Goodman, Ann S Hamilton, Antoinette Stroup, Tatsuki Koyama

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Patient-Centered Outcomes Research Institute
  • AHRQ HHS
  • NIH HHS
  • National Institutes of Health
  • Agency for Healthcare Research and Quality
  • National Center for Advancing Translational Sciences

Zitieren

APA

Baskin, A. S., Hoffman, K. E., Penson, D. F., Huang, L. C., Zhao, Z., Awamlh, B. A. H. A., Joyce, D. D., Morgans, A. K., Tosoian, J. J., Wallis, C. J. D., Goodman, M., Hamilton, A. S., Wu, X. C., Paddock, L. E., Stroup, A., O'Neil, B. B., Koyama, T., & Barocas, D. A. (2026). Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer. BJU International, 138(6), 1053-1064. https://doi.org/10.1111/bju.70410

Vancouver

Baskin AS, Hoffman KE, Penson DF, Huang LC, Zhao Z, Awamlh BAHA, et al. Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer. BJU International. 2026;138(6):1053-1064. doi:10.1111/bju.70410

BibTeX
@article{Baskin2026,
  author = {Baskin, Avi S and Hoffman, Karen E and Penson, David F and Huang, Li-Ching and Zhao, Zhiguo and Awamlh, Bashir Al Hussein Al and Joyce, Daniel D and Morgans, Alicia K and Tosoian, Jeffrey J and Wallis, Christopher J D and Goodman, Michael and Hamilton, Ann S and Wu, Xiao-Cheng and Paddock, Lisa E and Stroup, Antoinette and O'Neil, Brock B and Koyama, Tatsuki and Barocas, Daniel A},
  title = {Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {6},
  pages = {1053--1064},
  doi = {10.1111/bju.70410}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche